Why the study?
Does histidine-tryptophan-ketoglutarate solution provide similar myocardial protection compared to cold blood cardioplegic solution in pediatric patients undergoing cardiac surgery?
Does histidine-tryptophan-ketoglutarate solution provide similar myocardial protection compared to cold blood cardioplegic solution in pediatric patients undergoing cardiac surgery?
HTK solution provides comparable myocardial protection to cold blood cardioplegia in simple pediatric cardiac surgery, offering the advantage of a single-dose administration.
May support HTK as alternative to CBC for pediatric myocardial protection; hypothesis-generating and requires randomized confirmation.
Background: There is limited data on comparisons between the effect of histidin-etryptophan-ketoglutarate (HTK) solution and cold blood cardioplegic (CBC) solution in pediatric cardiac surgery. The purpose of this study was to compare the myocardial protective effect of HTK solution and CBC solution in patients undergoing pediatric cardiac surgery. Materials and Methods: We selected 49 patients with ventricular septal defect and atrial septal defect. HTK solution was used in 21 patients and CBC solution was used in 28 patents. HTK solution was given as a single dose, whereas CBC solution was used in the usual multi-dose method. The incidence of EKG change and concentration of Troponin T and CK-MB were compared for the evaluation of myocardial damage. Results: There were no significant differences in the incidence of ST, T segment change by EKG and serial cardiac enzyme levels between two groups. Conclusion: These results suggested that the myocardial protective effect of HTK solution was similar to CBC solution in simple pediatric cardiac surgery.
No takes yet. Share an insight, caveat, or question.
Jung et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: